hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06276179, orgStudyIdInfo id: KFSIRB200-97, briefTitle: Epidural Oxycodone for Pain Management for Lower Limb Amputation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-24, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Kafrelsheikh University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effect of epidural oxycodone for pain management after lower limb amputation., conditionsModule conditions: Epidural, conditions: Oxycodone, conditions: Pain, conditions: Lower Limb Amputation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Oxycodone, interventions name: Bupivacaine, outcomesModule primaryOutcomes measure: Acute postoperative pain scores, secondaryOutcomes measure: Time to the first request for the rescue analgesia, secondaryOutcomes measure: Postoperative morphine consumption, secondaryOutcomes measure: Incidence of phantom limb pain, secondaryOutcomes measure: Adverse effects, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kafrelsheikh University, status: RECRUITING, city: Kafr Ash Shaykh, state: Kafrelsheikh, zip: 33516, country: Egypt, contacts name: Gamal H Shams, MD, role: CONTACT, phone: 00201095927971, email: gamal.shams2@gmail.com, contacts name: Ahmed A Ghareeb, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mohamed H Osman, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Heba F Dawood, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mohamed M Kotb, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.11174, lon: 30.93991, hasResults: False
protocolSection identificationModule nctId: NCT06276166, orgStudyIdInfo id: 72374215, briefTitle: Trajectory of Frailty and Cognitive Dysfunction in Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Zheng Li, class: OTHER, descriptionModule briefSummary: To explore the heterogeneity of the development trend of frailty and cognitive function of older adults., conditionsModule conditions: Frailty, conditions: Cognitive Dysfunction, conditions: Community-dwelling Older Adults, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 934, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Frailty, primaryOutcomes measure: Cognitive function, otherOutcomes measure: Health status and life style, otherOutcomes measure: Activities of daily life (ADLs), otherOutcomes measure: Anxiety, otherOutcomes measure: Apathy, otherOutcomes measure: Perceived social support, otherOutcomes measure: Social network, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276153, orgStudyIdInfo id: CRGGCext, briefTitle: Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer, acronym: CRGGCext, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-02-28, completionDateStruct date: 2029-02-28, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder. Based on the database, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy., conditionsModule conditions: Biliary Tract Diseases, conditions: Gallbladder Cancer, conditions: Gallbladder Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 5000, type: ESTIMATED, armsInterventionsModule interventions name: no interventions, outcomesModule primaryOutcomes measure: overall survival, secondaryOutcomes measure: progression-free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276101, orgStudyIdInfo id: NEWISH-HPV-101, briefTitle: NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-07-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Newish Technology (Beijing) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL., conditionsModule conditions: High-grade Squamous Intraepithelial Lesion (HSIL), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: NWRD08 administered by electroporation, outcomesModule primaryOutcomes measure: Safety, primaryOutcomes measure: Dose-limiting toxicity (DLT), secondaryOutcomes measure: Immunogenicity, secondaryOutcomes measure: Histopathology outcome and HPV Viral clearance, secondaryOutcomes measure: The recommended phase II dose (RP2D), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Fang Jiang, M.D., role: CONTACT, phone: 86-010-69155635, email: 13671170943@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06276075, orgStudyIdInfo id: 10/KRN/2020, briefTitle: The Impact of Erigo®Pro Therapy and Motor Imagery on the Balance of Stroke Patients., statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-15, primaryCompletionDateStruct date: 2023-05-10, completionDateStruct date: 2023-09-10, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Anna Olczak, class: OTHER, descriptionModule briefSummary: The aim of the study is to examine the impact of motor imagery, Erigo®Pro tilt table intervention, and classic rehabilitation on the balance of people after a stroke., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 66, type: ACTUAL, armsInterventionsModule interventions name: Conventional rehabilitation, the Erigo®Pro table, motor imagery, outcomesModule primaryOutcomes measure: Trunk Control Test, primaryOutcomes measure: Berg Balance Scale, primaryOutcomes measure: RiabloTM device, primaryOutcomes measure: RiabloTM device, primaryOutcomes measure: Luna EMG, primaryOutcomes measure: Luna EMG, eligibilityModule sex: ALL, minimumAge: 38 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Military Institute of Medicine, city: Warsaw, state: Masovian District, zip: 04-141, country: Poland, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06276062, orgStudyIdInfo id: Titanium nail usage, briefTitle: Uses of Titanium Nail in Pediatric Fractures, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the short term functional and radiological outcomes of using double short titanium elastic nails as treatment of pediatric distal radius fractures., conditionsModule conditions: Trauma Injury of Upper Extremity Forearm Multiple, conditions: Fracture of Distal End of Radius, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Distal radius fracture fixation in pediatrics., outcomesModule primaryOutcomes measure: Comparison between usage of titanium nail and old methods, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Sohag university, status: RECRUITING, city: Sohag, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06276049, orgStudyIdInfo id: DGETRRP2023-54, briefTitle: ChatGPT Helping Advance Training for Medical Students: A Study on Self-Directed Learning Enhancement, acronym: CHAT-MS, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-25, primaryCompletionDateStruct date: 2024-01-06, completionDateStruct date: 2024-03-02, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Wang Shalong, class: OTHER, collaborators name: Central South University, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the effect of LearnGuide, a custom GPT developed with ChatGPT for supporting self-directed learning (SDL) in medical students. The main questions it aims to answer are:How does LearnGuide influence SDL skills among medical students? Can LearnGuide improve critical thinking and learning flow as measured by Cornell Critical Thinking Test (CCTT) Level Z score and Global Flow Score (GFS)?Participants will:Undergo a two-hour introduction to LearnGuide. Engage in 12 weeks of SDL task-based training with LearnGuide\&amp;#39;s support.If there is a comparison group: Researchers will compare the group utilizing LearnGuide for SDL and the group without this tool to see if there is a significant difference in SDL skills, critical thinking, and learning flow experiences., conditionsModule conditions: Self-Directed Learning, conditions: Artificial Intelligence, conditions: Medical Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 103, type: ACTUAL, armsInterventionsModule interventions name: custom GPT supported self-directed learning, outcomesModule primaryOutcomes measure: Self-Directed Learning Scale, secondaryOutcomes measure: Cornell Critical Thinking Test (CCTT) Level Z, secondaryOutcomes measure: Flow Short Scale, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Geriatirc Surgery, city: Changsha, state: Hunan, zip: 410011, country: China, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06276036, orgStudyIdInfo id: CAPID, briefTitle: Autoimmune Cytopenias as a Sign of Primary Immunodeficiency., statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2019-07-23, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Meyer Children's Hospital IRCCS, class: OTHER, descriptionModule briefSummary: Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies, conditionsModule conditions: Cytopenia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 53, type: ACTUAL, armsInterventionsModule interventions name: Identification of specific markers, outcomesModule primaryOutcomes measure: Identification of specific markers, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of South Florida, city: Tampa, state: Florida, zip: 33620, country: United States, geoPoint lat: 27.94752, lon: -82.45843, locations facility: Ghent University Hospital, city: Ghent, country: Belgium, geoPoint lat: 51.05, lon: 3.71667, locations facility: Clinica Pediatrica - Università di Catania, city: Catania, country: Italy, geoPoint lat: 37.49223, lon: 15.07041, locations facility: Meyer Children's Hospital IRCCS, city: Florence, country: Italy, geoPoint lat: 43.77925, lon: 11.24626, locations facility: IRCCS Istituto Giannina Gaslini, city: Genova, country: Italy, geoPoint lat: 44.40478, lon: 8.94438, locations facility: Azienda Ospedaliero Universitaria Pisana, city: Pisa, country: Italy, geoPoint lat: 43.70853, lon: 10.4036, hasResults: False
protocolSection identificationModule nctId: NCT06276010, orgStudyIdInfo id: 2023-102, briefTitle: Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Xiaotong Hou, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery., conditionsModule conditions: Extracorporeal Membrane Oxygenation Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: nafamostat mesilate, interventions name: unfractionated heparin group, outcomesModule primaryOutcomes measure: Incidence of thrombotic complications, secondaryOutcomes measure: Incidence of severe bleeding complications, secondaryOutcomes measure: Infusion volume of blood products, secondaryOutcomes measure: ACT qualified rate, secondaryOutcomes measure: Hospitalization mortality, secondaryOutcomes measure: The incidence of oxygenator dysfunction, secondaryOutcomes measure: Heparin-induced thrombocytopenia, secondaryOutcomes measure: Time to reach the target anticoagulant level for the first time, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Anzhen Hospital, city: Beijing, state: Beijing, zip: 100029, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06275997, orgStudyIdInfo id: GAIN, briefTitle: GAIN Project: Gastric Cancer and Artificial Intelligence, acronym: GAIN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Istituto Clinico Humanitas, class: OTHER, descriptionModule briefSummary: Our GAIN project comprises four core work packages (WPs): WP1. Nation-level randomized controlled trial; WP2. Development of an innovative AI tool; WP3. Novel microsimulation modelling; WP4. Patient inclusion.The nation-level multi-center tandem randomized controlled trial (WP1) will contribute to a better understanding of how the real-time AI algorithm can reduce miss rate of early gastric cancer and dysplasia during gastroscopy. Moreover, the innovation project will contribute to development of a novel AI tool (WP2) that can stratify the risk of gastric cancer by identifying in vivo precancerous conditions. Furthermore, a microsimulation modelling will allow us to predict how the use of AI can prevent gastric cancer and affect cost and patients' burdens. The assessment of the balance between benefits and harms is quite crucial especially for this type of medical device because the value of innovative tools is sometimes overestimated due to stakeholders' enthusiasm (WP3). Finally, we will take care of patients' perspective throughout the study project by including patient organization in both WP1, 2, and 3 (WP4)., conditionsModule conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel/Crossover Study Model; Patients will be randomized 1:1:1:1, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 6600, type: ESTIMATED, armsInterventionsModule interventions name: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy, outcomesModule primaryOutcomes measure: Miss rate reduction, secondaryOutcomes measure: Change number of Detections, secondaryOutcomes measure: patient satisfaction, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06275945, orgStudyIdInfo id: 1010073, briefTitle: Feasibility Study of A VoRo UrologIc ScaffolD (ARID), acronym: ARID, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-03, primaryCompletionDateStruct date: 2026-07-30, completionDateStruct date: 2026-10-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Levee Medical, Inc., class: INDUSTRY, collaborators name: RQMplus, descriptionModule briefSummary: The objective of this study is to evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence.The study is a prospective, multicenter, single arm study. Up to 40 subjects will be treated at up to 3 investigational sites in Panama. Subjects will be followed up post-treatment at catheter removal, 6 weeks post prostatectomy, 3 months, 6 months, 12 months and 2 years., conditionsModule conditions: Stress Urinary Incontinence, conditions: Radical Prostatectomy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, non-randomized first-in-man study, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Voro Urologic Scaffold, outcomesModule primaryOutcomes measure: The change in pad weight of 24-hour pad weight test from baseline to post procedure 6-month and 12-month follow-ups., secondaryOutcomes measure: The change in pad weight of 1-hour pad weight test from baseline to post procedure 6-month and 12-month follow-ups., secondaryOutcomes measure: The changes in the standing cough test (SCT) from baseline to post procedure 6-month and 12-month follow-ups., eligibilityModule sex: MALE, minimumAge: 45 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Hospital, status: RECRUITING, city: Panama City, state: Punta Pacifica, country: Panama, contacts name: Natalia Vega, role: CONTACT, email: nvega@candmresearch.org, contacts name: Margelis Munoz, role: CONTACT, phone: 507-6499-9304, email: mmunoz@candmresearch.org, contacts name: Gustavo Espino, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 8.9936, lon: -79.51973, hasResults: False